Funds and ETFs Chembio Diagnostics, Inc.

Chembio Diagnostics, Inc. is a diagnostics company. The Company is focused on developing and commercializing point-of-care tests used to detect and diagnose infectious diseases, including sexually transmitted diseases, insect vectors and tropical diseases, coronavirus disease (COVID-19), and other viral and bacterial infections, enabling expedited treatment. The Company's DPP technology offers broad market applications beyond infectious disease. The DPP platform can detect and differentiate up to eight distinct test results from a single patient sample. Its DPP Micro Reader optical analyzers can report results in approximately 15 seconds, making it well-suited for decentralized testing where real-time results enable patients to be clinically assessed while they are still on site. Its products are sold globally, directly and through distributors, to hospitals and clinics, physician offices, clinical laboratories, public health organizations, government agencies, and consumers.